401 related articles for article (PubMed ID: 15788977)
1. Optimal antithrombotic treatment for percutaneous coronary intervention.
Kadakia RA; Ferguson JJ
Minerva Cardioangiol; 2005 Feb; 53(1):15-42. PubMed ID: 15788977
[TBL] [Abstract][Full Text] [Related]
2. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
Ferguson JJ; Wilson JM; Diez J
Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162
[TBL] [Abstract][Full Text] [Related]
3. Debate of adjunctive pharmacology for percutaneous coronary intervention: anticoagulation and clopidogrel are not (always) enough.
Tcheng JE
J Interv Cardiol; 2006 Oct; 19(5):456-63. PubMed ID: 17020571
[TBL] [Abstract][Full Text] [Related]
4. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
Savonitto S; Ambrosini V; Marzocchi A; Tolaro S; Petronio AS; Galassi AR; Bongo AS; Gaglione A; Bolognese L; ;
Ital Heart J; 2005 Feb; 6(2):106-18. PubMed ID: 15819503
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic drugs in vascular medicine: a historical perspective.
Schrör K
Semin Vasc Med; 2003 May; 3(2):97-105. PubMed ID: 15199472
[TBL] [Abstract][Full Text] [Related]
6. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
[TBL] [Abstract][Full Text] [Related]
7. What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention?
Steinhubl S; Berger P
Am Heart J; 2003 Jun; 145(6):971-8. PubMed ID: 12796751
[TBL] [Abstract][Full Text] [Related]
8. Drug insight: antithrombotic therapy after percutaneous coronary intervention in patients with an indication for anticoagulation.
Helft G; Gilard M; Le Feuvre C; Zaman AG
Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):673-80. PubMed ID: 17122800
[TBL] [Abstract][Full Text] [Related]
9. Drugs for percutaneous coronary interventions.
Med Lett Drugs Ther; 2004 Dec 6-20; 47(1197-1198):100-2. PubMed ID: 15583527
[TBL] [Abstract][Full Text] [Related]
10. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
[TBL] [Abstract][Full Text] [Related]
11. Rationale for low-molecular weight heparin in coronary stenting.
Zidar JP
Am Heart J; 1997 Nov; 134(5 Pt 2):S81-7. PubMed ID: 9396639
[TBL] [Abstract][Full Text] [Related]
12. Anti-platelet and anti-thrombotic approaches in patients undergoing percutaneous coronary intervention.
Garg R; Uretsky BF; Lev EI
Catheter Cardiovasc Interv; 2007 Sep; 70(3):388-406. PubMed ID: 17722043
[TBL] [Abstract][Full Text] [Related]
13. Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding.
May AE; Geisler T; Gawaz M
Thromb Haemost; 2008 Mar; 99(3):487-93. PubMed ID: 18327396
[TBL] [Abstract][Full Text] [Related]
14. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulant and/or antiplatelet treatment in patients with atrial fibrillation after percutaneous coronary intervention. A single-center experience.
Maegdefessel L; Schlitt A; Faerber J; Bond SP; Messow CM; Buerke M; Raaz U; Werdan K; Muenzel T; Weiss C
Med Klin (Munich); 2008 Sep; 103(9):628-32. PubMed ID: 18813885
[TBL] [Abstract][Full Text] [Related]
16. The role of platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization procedures.
Dangas G; Fuster V
Rev Port Cardiol; 1999 Feb; 18 Suppl 1():I49-53. PubMed ID: 10191675
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet therapy in percutaneous coronary intervention: a critical review of the 2007 AHA/ACC/SCAI guidelines and beyond.
Cohen M
Catheter Cardiovasc Interv; 2009 Oct; 74(4):579-97. PubMed ID: 19472347
[TBL] [Abstract][Full Text] [Related]
18. [Current approach in antithrombotic treatment during coronary interventions: specific thrombocyte aggregation inhibitors and direct thrombin antagonists in high-risk patients].
Meyer BJ
Schweiz Med Wochenschr; 1996 Nov; 126(46):1961-9. PubMed ID: 8984604
[TBL] [Abstract][Full Text] [Related]
19. Platelet activation and progression to complications.
Kereiakes DJ; Michelson AD
Rev Cardiovasc Med; 2006; 7(2):75-81. PubMed ID: 16915126
[TBL] [Abstract][Full Text] [Related]
20. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor.
Gurbel PA
Rev Cardiovasc Med; 2006; 7 Suppl 4():S20-8. PubMed ID: 17224887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
